Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around

Description

Summary

This randomized, double-blind, single-site phase II 2-arm study will investigate the safety and preliminary efficacy of MDMA-assisted therapy compared with low dose d-amphetamine-assisted therapy on the severity of PTSD symptoms in participants aged 18 years and older with PTSD of at least moderate severity.

Official Title

A Randomized, Double-Blind, Single-Site Phase II 2-Arm Study to Compare the Safety and Preliminary Efficacy of Manualized MDMA-Assisted Therapy to Low Dose D-Amphetamine Assisted Therapy in Veterans for the Treatment of Moderate to Severe PTSD

Details

This randomized, double-blind, single-site phase II 2-arm study will compare MDMA-assisted therapy with low dose d-amphetamine-assisted therapy to treat PTSD symptoms in veteran participants aged 18 years and older with PTSD of at least moderate severity, as measured by the change in CAPS-5 total severity score. The study will be conducted in up to N=40 participants from the Greater Los Angeles VA randomized with a 1:1 allocation to Group 1: MDMA-assisted therapy or Group 2: low dose d-amphetamine assisted therapy.

For each participant, the study will consist of:

  • Screening Period: phone screen, informed consent, eligibility assessment, Screening CAPS-5, and Initial Enrollment of eligible participants.
  • Preparatory Period: medication tapering, three Preparatory Sessions, baseline assessments (including Baseline CAPS-5), leading to Enrollment Confirmation.
  • Treatment Period: three Experimental Sessions, and three Integrative Sessions following each Experimental Session including CAPS-5 assessments.
  • Follow-up Period and Study Termination: Primary Outcome CAPS-5 assessment and Study Termination visit.

Keywords

Post Traumatic Stress Disorder, MDMA, PTSD, Functional Impairment, Veteran, Substance Use Disorder, Chronic Pain, Traumatic Stress Disorders, Post-Traumatic Stress Disorders, Amphetamine, Dextroamphetamine, N-Methyl-3,4-methylenedioxyamphetamine, 3,4-methylenedioxymethamphetamine, d-amphetamine, Therapy, MDMA-Assisted Therapy

Eligibility

You can join if…

Open to people ages 18 years and up

  • At Screening, meet DSM-5 criteria for current PTSD with a symptom duration of at least 6 months.
  • Fluent in speaking and reading the predominantly used or recognized language of the study site (English).
  • Must be a veteran enrolled at a VA Healthcare Center in the Greater Los Angeles area.
  • Able to swallow pills.
  • Agree to have study visits audiovisually recorded, including Experimental Sessions, IR assessments, and non-drug therapy sessions.
  • Able to provide a contact (relative, spouse, close friend, or other support person) who is willing and able to be reached by the investigators in the event of the participant becoming unwell or unreachable.
  • Able to identify appropriate support person(s) to stay with the participant on the evenings of Experimental Sessions if needed.
  • May have well-controlled hypertension that has been successfully treated with anti-hypertensive medicines, if they pass additional screening to rule out underlying cardiovascular disease.
  • May have asymptomatic Hepatitis C virus (HCV) that has previously undergone evaluation and treatment as needed.
  • Body weight of at least 45 kilograms (kg). Participants with a body weight of 45-48 kg must also have a body mass index (BMI) within the range of 18 to 30 kg/m2. BMI must be within 18 to 32 kg/m2 (inclusive).
  • A person able to be pregnant (PABP) must use a highly effective contraceptive method.

You CAN'T join if...

  • Are not able to give adequate informed consent.
  • Have evidence or history of significant medical or psychiatric disorders.
  • Are abusing illegal drugs.
  • Unable or unwilling to safely taper off prohibited psychiatric medication.
  • Current enrollment in any other clinical study involving an investigational study treatment or any other type of medical research, unless approved by the study clinician.

Locations

  • West Los Angeles Veteran Affairs accepting new patients
    Los Angeles California 90095 United States
  • VA Greater Los Angeles Healthcare System, Westwood campus not yet accepting patients
    Los Angeles California 90073 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Stephen Robert Marder
ID
NCT05790239
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 40 study participants
Last Updated